乙肝临床治愈:欣喜与期待  

Clinical cure of hepatitis B:Delight and anticipation

作　　者：李亚萍[1] 刘晨瑞 郝苗 鲁瑞 党双锁[1] Ya-Ping Li;Chen-Rui Liu;Miao Hao;Rui Lu;Shuang-Suo Dang(Department of Infectious Diseases,Second Affiliated Hospital of Xi’an Jiaotong University,Xi’an 710004,Shaanxi Province,China)

机构地区：[1]西安交通大学第二附属医院感染科,陕西省西安市710004

出　　处：《世界华人消化杂志》2023年第20期837-845,共9页World Chinese Journal of Digestology

摘　　要：慢性乙型肝炎(chronic hepatitis B,CHB)患者实现临床治愈代表患者获得了持久的病毒学抑制和免疫学控制,是目前国内外CHB防治指南的理想治疗目标.临床实践证明,以核苷(酸)类似物(nucleus(t)ide analogs,NAs)或免疫调节剂(如聚乙二醇干扰素α)序贯或联合治疗的优化方案针对部分优势人群取得了令人欣喜的结果,但在临床上乙肝治愈欣喜的同时仍有相当多的患者还不能实现临床治愈的目标,要达到较好的治疗效果诸多难题仍需要跨越.本文就乙肝临床治愈目前的研究进展与存在问题做一简要述评.Chronic hepatitis B(CHB)patients achieving clinical cure represent individuals who have attained persistent virological suppression and immunological control.This is the ideal treatment goal in both domestic and international CHB management guidelines.Clinical practice has demonstrated promising outcomes for certain patient populations treated with optimized regimens involving nucleos(t)ide analogs(NAs)or immunomodulators(such as pegylated interferonα)administered sequentially or in combination.However,despite the gratifying progress in the clinical management of hepatitis B,a significant number of patients still cannot achieve the goal of clinical cure.Many challenges remain to be overcome to achieve better treatment outcomes.This article provides a brief overview of the current research progress and existing issues in the pursuit of clinical cure of hepatitis B.

关 键 词：慢性乙型病毒性肝炎 临床治愈 研究进展 

分 类 号：R512.62[医药卫生—内科学]